Daniel Joseph OConnell

CIK: 0001865136

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)10 (83.3%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (16.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ABOS

Acumen Pharmaceuticals, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (12 total)

ABOS
Acumen Pharmaceuticals, Inc.
Jan 22, 2026
Sale(S)
Direct
2.7K shares at avg. $1.88$5K
ABOS
Acumen Pharmaceuticals, Inc.
Jan 21, 2026
Sale(S)
Direct
9.3K shares at avg. $1.81$17K
ABOS
Acumen Pharmaceuticals, Inc.
Jan 20, 2026
Award(A)
Direct
299.8K shares-
ABOS
Acumen Pharmaceuticals, Inc.
Jan 12, 2026
Sale(S)
Direct
5.4K shares at avg. $1.73$9K
ABOS
Acumen Pharmaceuticals, Inc.
Jan 9, 2026
Sale(S)
Direct
12.9K shares at avg. $1.76$23K
ABOS
Acumen Pharmaceuticals, Inc.
Jan 8, 2026
Sale(S)
Direct
8.1K shares at avg. $1.82$15K
ABOS
Acumen Pharmaceuticals, Inc.
Jan 7, 2026
Sale(S)
Direct
37.8K shares at avg. $1.99$75K
ABOS
Acumen Pharmaceuticals, Inc.
Jan 6, 2026
Sale(S)
Direct
5.1K shares at avg. $1.97$10K
ABOS
Acumen Pharmaceuticals, Inc.
Jan 5, 2026
Sale(S)
Direct
4.6K shares at avg. $1.97$9K
ABOS
Acumen Pharmaceuticals, Inc.
Jan 21, 2025
Sale(S)
Direct
12.6K shares at avg. $1.59$20K
ABOS
Acumen Pharmaceuticals, Inc.
Jan 7, 2025
Award(A)
Direct
225.4K shares-
ABOS
Acumen Pharmaceuticals, Inc.
Jan 3, 2025
Sale(S)
Direct
47.8K shares at avg. $1.84$88K

		Type	Shares	Price		Ownership
Jan 22, 2026	ABOS Acumen Pharmaceuticals, Inc.	Sale(S)	2,689	$1.88	$5,066	Direct
Jan 21, 2026	ABOS Acumen Pharmaceuticals, Inc.	Sale(S)	9,346	$1.81	$16,927	Direct
Jan 20, 2026	ABOS Acumen Pharmaceuticals, Inc.	Award(A)	299,800	-	$0	Direct
Jan 12, 2026	ABOS Acumen Pharmaceuticals, Inc.	Sale(S)	5,388	$1.73	$9,307	Direct
Jan 9, 2026	ABOS Acumen Pharmaceuticals, Inc.	Sale(S)	12,941	$1.76	$22,832	Direct
Jan 8, 2026	ABOS Acumen Pharmaceuticals, Inc.	Sale(S)	8,143	$1.82	$14,815	Direct
Jan 7, 2026	ABOS Acumen Pharmaceuticals, Inc.	Sale(S)	37,755	$1.99	$74,981	Direct
Jan 6, 2026	ABOS Acumen Pharmaceuticals, Inc.	Sale(S)	5,102	$1.97	$10,032	Direct
Jan 5, 2026	ABOS Acumen Pharmaceuticals, Inc.	Sale(S)	4,649	$1.97	$9,163	Direct
Jan 21, 2025	ABOS Acumen Pharmaceuticals, Inc.	Sale(S)	12,619	$1.59	$20,102	Direct
Jan 7, 2025	ABOS Acumen Pharmaceuticals, Inc.	Award(A)	225,400	-	$0	Direct
Jan 3, 2025	ABOS Acumen Pharmaceuticals, Inc.	Sale(S)	47,778	$1.84	$87,873	Direct

1-12 of 12 transactions

About OConnell Daniel Joseph

OConnell Daniel Joseph (SEC CIK 0001865136) files insider reports with the SEC as Chief Executive Officer of Acumen Pharmaceuticals, Inc. (ABOS).

Signal8 holds 6 ownership filings by OConnell Daniel Joseph, all Form 4s, filed between Jan 7, 2025 and Jan 23, 2026. Those filings report 12 transactions, from Jan 3, 2025 to Jan 22, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on OConnell Daniel Joseph's filings is in NEWTON, MA.

Recent filings by OConnell Daniel Joseph

Jan 22, 2026: Open-market sale of ABOS shares (Form 4, code S).
Jan 21, 2026: Open-market sale of ABOS shares (Form 4, code S).
Jan 20, 2026: Grant or award of ABOS shares (Form 4, code A).
Jan 12, 2026: Open-market sale of ABOS shares (Form 4, code S).
Jan 9, 2026: Open-market sale of ABOS shares (Form 4, code S).

Other insiders filing for Acumen Pharmaceuticals, Inc. (ABOS)

How to read Form 4 transaction codes